

JUL 27 2005

Application Ser. No.: 10/783,451

Filing Date: February 20, 2004

Examiner: Spivack, Phyllis G.

**Amendment Pursuant to 37 C.F.R. § 1.121****IN THE CLAIMS:**

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (original) A pharmaceutical composition comprising at least about 50 mg to about 600 mg of cyamemazine in combination with an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
2. (original) The composition according to claim 1, wherein cyamemazine is present in an amount of from about 75 mg to about 500 mg.
3. (original) The composition according to claim 1 wherein the atypical neuroleptic is sertindole.
4. (original) The composition according to claim 2 wherein the atypical neuroleptic is sertindole.
5. (original) The composition according to claim 1 wherein the atypical neuroleptic is quetiapine.
6. (original) The composition according to claim 2 wherein the atypical neuroleptic is quetiapine.
7. (original) The composition according to claim 1 wherein the atypical neuroleptic is ziprasidone.

Application Ser. No.: 10/783,451  
Filing Date: February 20, 2004  
Examiner: Spivack, Phyllis G.

8. (original) The composition according to claim 2 wherein the atypical neuroleptic is ziprasidone.
9. (original) The composition according to claim 1, wherein cyamemazine and the atypical neuroleptic are in pure state or in the presence of any compatible and pharmaceutically acceptable diluent or adjuvant.
10. (original) A method for preparing a composition as defined in claim 1 comprising the step of mixing at least about 50 mg of cyamemazine with a suitable amount of an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
11. (original) A method for treating a patient suffering from schizophrenic disorders comprising administering to said patient an effective amount of a combination of cyamemazine and an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
12. (original) The method according to claim 11 wherein cyamemazine is present in an amount of from about 50 mg to about 600 mg.
13. (original) The method according to claim 11 wherein the atypical neuroleptic is sertindole.
14. (original) The method according to claim 11 wherein the atypical neuroleptic is quetiapine.

Application Ser. No.: 10/783,451  
Filing Date: February 20, 2004  
Examiner: Spivack, Phyllis G.

15. (original) The method according to claim 11 wherein the atypical neuroleptic is ziprasidone.
16. (original) The method according to claim 11 wherein the patient is suffering from acute episodes of schizophrenia.
17. (original) The method according to claim 11 wherein cyamemazine and the neuroleptic are administered simultaneously or separately or in a manner spread out over time.
18. (original) The method according to claim 17 wherein cyamemazine and the neuroleptic are administered simultaneously.
19. (original) The method according to claim 17 wherein cyamemazine and the neuroleptic are administered separately.
20. (original) The method according to claim 17 wherein cyamemazine and the neuroleptic are administered in a manner spread out over time.
21. canceled